# Inventiva: last NATiV3 patient completes 72 weeks; lanifibranor topline on track for Q4 2026

Canonical page: https://technooptimist.io/stories/inventiva-last-nativ3-patient-completes-72-weeks-lanifibranor-topline-657779d3
Date: 28 Sep 2026
About: [Inventiva](https://technooptimist.io/companies/inventiva.md) · [Lanifibranor](https://technooptimist.io/biotech/lanifibranor.md)
Original source: https://www.marketbeat.com/instant-alerts/transcript-inventiva-q2-earnings-call-highlights-2026-09-28/

On its Q2 2026 call, Inventiva said the final NATiV3 patient finished the 72-week visit in September and topline results remain due in Q4 2026. If positive, it plans a US filing in the first half of 2027 for accelerated approval, conditional approval in Europe, and an outcomes trial in cirrhosis. The company holds €233.9M in cash, enough into Q2 2027.

## Key facts

- Primary endpoint: MASH resolution plus one-stage fibrosis improvement in the same patient; 90% power on conservative assumptions.
- Phase 2b NATIVE (6 months): placebo-adjusted +18% fibrosis, +26% MASH resolution, +24% composite.
- Exploratory cohort includes roughly 75–100 cirrhotic patients treated at least 18 months.
- Possible US launch in 2028.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.